Sofosbuvir plus ribavirin without interferon for treatment of acute hepatitis c virus infection in HIV-1-infected individuals: SWIFT-C

Clinical Infectious Diseases

Volumn 64, Issue 8, 2017, Pages 1035-1042

  Naggie, Susanna ^a   Marks, Kristen M ^b   Hughes, Michael ^c   Fierer, Daniel S ^d   Macbrayne, Christine ^e   Kim, Arthur ^f   Hollabaugh, Kimberly ^g   Roa, Jhoanna ^g   Symonds, Bill ^h   Brainard, Diana M ⁱ   McHutchison, John G ⁱ   Peters, Marion G ^j   Kiser, Jennifer J ^e   Chung, Raymond ^f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Weill Cornell Medical School   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^h Roivant ^*  (United States)

ⁱ GILEAD SCIENCES   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

direct acting antivirals; early infection; hepatitis; human immunodeficiency virus; interferon free

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; HEMOGLOBIN; INTERFERON; INTERLEUKIN 28B; RIBAVIRIN; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT;

ACUTE HEPATITIS C; ADULT; ADVERSE EVENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIRETROVIRAL THERAPY; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C VIRUS GENOTYPE 1; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; TREATMENT DURATION; CLINICAL TRIAL; COMPLICATION; HEPATITIS C; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MIDDLE AGED; RECURRENT DISEASE; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RIBAVIRIN; SOFOSBUVIR; TREATMENT OUTCOME;

EID: 85021308814     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix025     Document Type: Article

References (29)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705-14.
2. Centers for Disease Control and Prevention, C.f.D.C.a.P., Statistics and Surveillance. 2015.
3. Onofrey S, Aneja J, Haney GA, et al. Underascertainment of acute hepatitis C virus infections in the U.S. surveillance system: A case series and chart review. Ann Intern Med 2015; 163:254-61.
4. Zibbell JE, Iqbal K, Patel RC, et al; Centers for Disease Control and Prevention. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years-Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. Morb Mortal Wkly Rep 2015; 64:453-8.
5. Centers for Disease Control and Prevention, C.f.D.C.a.P., Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men-New York City, 2005-2010. Morb Mortal Wkly Rep 2011; 60:945-50.
6. Jaeckel E, Cornberg M, Wedemeyer H, et al; German Acute Hepatitis C Therapy Group. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345:1452-7.
7. Corey KE, Mendez-Navarro J, Gorospe EC, Zheng H, Chung RT. Early treatment improves outcomes in acute hepatitis C virus infection: A meta-analysis. J Viral Hepat 2010; 17:201-7.
8. Matthews GV, Hellard M, Haber P, et al; Australian Trial in Acute Hepatitis C Study Group. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis 2009; 48:650-8.
9. Boesecke C, Stellbrink HJ, Mauss S, et al. Does baseline HCV genotype have an impact upon treatment outcome of acute HCV infection in HIV co-infected individuals. 18th Conference on Retroviruses and Opportunistic Infections. February 27-March 2, 2011; Boston, MA., 2011. Abstract 113.
10. Sofosbuvir, U.S. prescribing information. Foster City, CA: Gilead Sciences, 2015.
11. European, A.T.N.A.H.C.I.C.P., Acute hepatitis C in HIV-infected individuals: Recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS 2011. 25: 399-409.
12. Deterding K, Gruner N, Buggisch P, et al; Hep-Net Acute HCV-III Study Group. Delayed versus immediate treatment for patients with acute hepatitis C: A randomised controlled non-inferiority trial. Lancet Infect Dis 2013; 13:497-506.
13. COPEGUS (RBV, U.T., US Prescribing Information. Roche Laboratories Inc., Nutley, NJ: P. Revised: February 2013.
14. US Department of Health and Human Services, N.I.o.H., National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0. [November 2014]. Available from: Http://rsc.tech-res.com/Document/safetyandpharmacovigilance/DAIDS-AE-GRADING-TABLE-v2-NOV2014.pdf.
15. Fierer DS, Dieterich DT, Mullen MP, et al; New York Acute Hepatitis C Surveillance Network. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis 2014; 58:873-9.
16. Hullegie SJ, Claassen MA, van den Berk GE, et al. Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients. J Hepatol 2016; 64:807-12.
17. Martinello M, Gane E, Hellard M, et al. Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study. Hepatology 2016; 64:1911-21.
18. Grady BP, Schinkel J, Thomas XV, Dalgard O. Hepatitis C virus reinfection following treatment among people who use drugs. Clin Infect Dis 2013; 57 Suppl 2:S105-10.
19. Ingiliz P, Krznaric I, Stellbrink HJ, et al. Multiple hepatitis C virus (HCV) reinfections in HIV-positive men who have sex with men: no influence of HCV genotype switch or interleukin-28B genotype on spontaneous clearance. HIV Med 2014; 15:355-61.
20. Turner BJ. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J Infect Dis 2002; 185 Suppl 2:S143-51.
21. Miller LG, Hays RD. Measuring adherence to antiretroviral medications in clinical trials. HIV Clin Trials 2000; 1:36-46.
22. Paterson DL, Potoski B, Capitano B. Measurement of adherence to antiretroviral medications. J Acquir Immune Defic Syndr 2002; 31 Suppl 3:S103-6.
23. Wu LS, Rower JE, Burton JR Jr, et al. Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother 2015; 59:2179-88.
24. Rower JE, Meissner EG, Jimmerson LC, et al. Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. J Antimicrob Chemother 2015; 70:2322-9.
25. Khakoo S, Glue P, Grellier L, et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: Assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998; 46:563-70.
26. Shih YC, Bekele NB, Xu Y. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients. Pharmacoeconomics 2007; 25:843-62.
27. Hatu G, Bailly F, Pourcelot E, et al. Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients. BMC Infect Dis 2014; 14:150.
28. Rockstroh J, Bhagani S, Hyland RH, et al. Ledipasvir/sofosbuvir for 6 weeks in HIV-infected patients with acute HCV infection. Conference on Retroviruses and Opportunistic Infections (CROI). February 22-25, 2016: P. Boston. Abstract 154LB.
29. Deterding K, Spinner CD, Schott E, et al. Ledipasvir plus sofosbuvir fixed-dose combination for six weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV I): An open-label, single-arm, phase 2 study. Lancet Infect Dis 2016. [Epub ahead of print]